Key Drivers
- Strong liquidity
- Large cash burn
- Negative profitability
AIAI Summary
Iovance has shifted from a binary clinical‑stage bet to an early commercial oncology story where successful Amtagvi adoption and flawless commissioning of the iCTC (driving sustained >45–50% gross margins) will determine whether the company converts improving revenue into durable profitability rather than needing dilutive financing. Monitor quarterly cash burn versus product revenue and specific iCTC commissioning/production metrics closely—positive surprises there materially reduce dilution risk, while manufacturing hiccups or slow ATC onboarding would rapidly worsen the outlook.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Large cash burn
- •Negative profitability
IOVA has ample cash and very low leverage but remains unprofitable with large R&D-driven operating losses and negative free cash flow that require financing, leaving valuation stretched despite premium multiples.
Price Behavior
Key Price Behavior Insights:
- •Short-term weakness
- •Below moving average
- •Elevated volatility
IOVA has suffered a sharp ~32% pullback from its last-month peak of $5.41 to $3.69 (trading ~9% below its last-month average of ~$4.06), showing short-term weakness, elevated volatility, and immediate support near $3.70–$3.90 with resistance around $4.10–$5.41.
Sharp ~32% drop from $5.41 to $3.69 over last month indicating elevated volatility
Sentiment & News
Key News Insights:
- •Strong Q4 results
- •50% ORR
- •Runway/manufacturing risk
Iovance delivered stronger-than-expected Q4 results and positive lifileucel pilot data that propelled a stock surge and analyst optimism, but material execution and financing risks remain.
Clinical and commercial momentum should support near-term share strength, but persistent manufacturing and cash-runway concerns could constrain sustained upside without clear execution or financing progress
Similar Companies in Healthcare
Other companies in the same sector with AI ratings